fromFast Company
1 week agoWegovy and Zepbound prices are dropping, but steady access to the weight-loss drugs remains a challenge
"The medications should be available, the question is at what price and can people sustain that," said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage.
Healthcare